WHO Issues Concern Over Critical Scarcity of Obesity Jabs
Under one in 10 patients who could benefit from GLP-1 drugs including Wegovy have access to them, states the global health agency as it releases its initial advice on the therapies.
Considering more than one billion individuals worldwide now living with obesity, it is calling for increased and just access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be treated with holistic and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to widespread access to the injections that can aid individuals in losing significant weight, says the body.
Weight-Loss Drug Shortage
Despite the present best projected case, the supply of these medications might only reach approximately 100 million people – less than 10% of those who need them, according to the health organization.
The recommendation encourages nations and manufacturers to widen availability, by measures including patent sharing.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs replicate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so users consume fewer calories.
Individuals commonly see weight reduction within a few weeks of starting on the weekly injections.
Research indicates users may regain a significant portion after a year of discontinuing the drug, when their typical appetite resume.
Being carrying excess weight increases your likelihood for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts people in every country and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
